Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2023042979

Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu

{"title":"Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.","authors":"Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042979","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042979","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.

查看原文本刊更多论文

目前治疗特应性皮炎的药物及配方研究进展。

特应性皮炎(AD)是一种慢性、复发性炎症性皮肤病，具有复杂的病理生理。由于存在广泛的临床表型和对现有疗法的有限反应，阿尔茨海默病的治疗仍然具有挑战性。然而，最近对疾病机制的遗传、免疫学和病理生理学见解导致了新的候选治疗药物的发明。这篇综述提供了目前治疗的全面概述，并评估了目前正在临床研究的各种新的给药策略。此外，本综述主要侧重于各种局部治疗，包括润肤疗法、屏障修复剂、局部皮质类固醇(TCS)、磷酸二酯酶4 (PDE4)抑制剂、钙调磷酸酶抑制剂和Janus激酶(JAK)信号转导和转录激活因子(STAT)途径抑制剂。它还讨论了基于正在进行的临床试验的生物和全身治疗，即将进行的治疗。此外，本综述审查了在已批准的用于AD治疗的外用剂型中药物非活性成分的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Reviews in Therapeutic Drug Carrier Systems 医学-药学

CiteScore

5.50

自引率

18.50%

发文量

审稿时长

>12 weeks

期刊介绍： Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.